Factors associated with altmetric attention scores for randomized phase III cancer clinical trials.

被引：0
|
作者：
Rooney, Michael Kevin
Ludmir, Ethan B.
Fuller, Clifton Dave
Warner, Jeremy Lyle
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11014
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A comparison of the top 500 papers in Clinical Nutrition ranked by citation and Altmetric Attention Scores
    Lewis-Lloyd, Christopher A.
    Lewis-Lloyd, C. A.
    Lobo, Dileep N.
    CLINICAL NUTRITION, 2024, 43 (08) : 1790 - 1797
  • [32] Control of false positives in randomized phase III clinical trials
    Shen, Changyu
    Liu, Ziyue
    Xu, Huiping
    Liu, Hai
    Yue, Cynthia
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (05) : 719 - 731
  • [33] Limitations of randomized clinical trials. Proposed alternative designs
    Cleophas, TJ
    Zwinderman, AH
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (12) : 1217 - 1223
  • [34] Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.
    Naseem, Madiha
    Berger, Martin D.
    Puccini, Alberto
    Tokunaga, Ryuma
    Battaglin, Francesca
    Barzi, Afsaneh
    Soni, Shivani
    McSkane, Michelle
    Cao, Shu
    Millstein, Joshua
    Zhang, Wu
    Loupakis, Fotios
    Stintzing, Sebastian
    Heinemann, Volker
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [35] Positive factors influencing hispanic/latina participation in breast cancer clinical trials.
    Samaras, Elizabeth
    Valdez, Sara
    ONCOLOGY NURSING FORUM, 2007, 34 (01) : 180 - 180
  • [36] Outcomes of patients with advanced cancer and KRAS mutation in phase I clinical trials.
    Tsimberidou, Apostolia Maria
    Said, Rabih
    Falchook, Gerald Steven
    Janku, Filip
    Naing, Aung
    Zinner, Ralph
    Blumenschein, George R.
    Fu, Siqing
    Hong, David S.
    Piha-Paul, Sarina Anne
    Wheier, Jennifer J.
    Ye, Yang
    Hess, Kenneth R.
    Palmer, Gary A.
    Wolff, Robert A.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Current phase III breast cancer clinical trials
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (07): : 696 - +
  • [38] Incidence and impact of proportional hazards violations in phase 3 cancer clinical trials.
    Lin, Timothy
    Koong, Alex
    Lin, Christine
    Jaoude, Joseph Abi
    Patel, Roshal
    Kouzy, Ramez
    El Alam, Molly Blue
    Noticewala, Sonal S.
    Sun, Ryan
    Fuller, Clifton Dave
    Thomas, Charles R.
    Mccaw, Zachary
    Ludmir, Ethan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Pharmaceutical involvement in breast cancer clinical trials.
    Peppercorn, JM
    Blood, E
    Winer, EP
    Partridge, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 542S - 542S
  • [40] Premature termination of genitourinary cancer clinical trials.
    Stensland, Kristian D.
    McBride, Russell
    Wisnivesky, Juan P.
    Latif, Asma
    Hendricks, Ryan
    Roper, Nitin
    Boffetta, Paolo
    Hall, Simon J.
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345